echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > ASKC202, a subsidiary of Aosaikang, obtained the notification of acceptance of clinical trial application

    ASKC202, a subsidiary of Aosaikang, obtained the notification of acceptance of clinical trial application

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 5, Osaikang issued an announcement stating that its wholly-owned subsidiary, Jiangsu Osaikang, had recently received the "Notice of Acceptance" for the ASKC202 new drug clinical trial application issued by the National Medical Products Administration


    ASKC202 tablet is a Class 1 new drug with independent intellectual property rights, and is a potent and highly selective oral small molecule c-MET inhibitor


    As a small molecule inhibitor targeting c-MET, ASKC202 has demonstrated its activity in a series of preclinical tumor models, and is expected to provide new treatment options for patients with abnormal tumors in the c-MET pathway


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.